Third Cycle Guidance For Rx-Price Negotiations Comes Alongside Govt. Shutdown

By Gabrielle Wanneh / October 1, 2025 at 7:15 PM

CMS Tuesday (Sept. 30) released final guidance for its third round of drug price negotiations, beginning next year, that incorporates the OBBBA’s controversial provision broadening how many orphan drugs can be excluded from the process.


Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.